{"eu_number": "EU-1-20-1492", "parse_date": "2022-11-29 19:27:18.407226", "decisions": [{"filename": "EU-1-20-1492_h_dec_0.pdf", "eu_aut_date": "2020-12-14 00:00:00", "eu_brand_name_initial": "Tecartus", "eu_brand_name_current": "Not parsed", "active_substance": "autologous anti-CD19-transduced  CD3+ cells", "eu_nas": true, "eu_atmp": true, "eu_od_initial": "adopted", "eu_mah_initial": "Kite Pharma EU B.V.", "eu_aut_type_initial": "conditional", "eu_aut_type_current": "Not parsed"}, {"filename": "EU-1-20-1492_h_dec_1.pdf", "eu_aut_date": "2021-11-18 00:00:00", "eu_brand_name_initial": "Tecartus", "eu_brand_name_current": "Not parsed", "active_substance": "autologous anti-CD19-transduced CD3+  cells", "eu_nas": false, "eu_atmp": false, "eu_od_initial": "Not parsed", "eu_mah_initial": "Not parsed", "eu_aut_type_initial": "Not parsed", "eu_aut_type_current": "conditional", "eu_mah_current": "Kite Pharma EU B.V."}, {"filename": "EU-1-20-1492_h_dec_2.pdf", "eu_aut_date": "2022-01-24 00:00:00", "eu_brand_name_initial": "Tecartus", "eu_brand_name_current": "Not parsed", "active_substance": "autologous anti-CD19-transduced CD3+ cells", "eu_nas": false, "eu_atmp": false, "eu_od_initial": "Not parsed", "eu_mah_initial": "Not parsed", "eu_aut_type_initial": "Not parsed", "eu_aut_type_current": "conditional", "eu_mah_current": "Kite Pharma EU B.V."}, {"filename": "EU-1-20-1492_h_dec_3.pdf", "eu_aut_date": "2022-02-09 00:00:00", "eu_brand_name_initial": "Autologous peripheral blood T cells  CD4 and CD 8 selected and CD 3 and CD 28 activated transduced with retroviral  vector expressing anti", "eu_brand_name_current": "Not parsed", "active_substance": "CD 19 CD 28/ CD 3-zeta chimeric antigen receptor and  cultured", "eu_nas": false, "eu_atmp": false, "eu_od_initial": "Not parsed", "eu_mah_initial": "Not parsed", "eu_aut_type_initial": "Not parsed", "eu_aut_type_current": "conditional", "eu_mah_current": "Kite Pharma EU B.V."}, {"filename": "EU-1-20-1492_h_dec_4.pdf", "eu_aut_date": "2022-11-15 00:00:00", "eu_brand_name_initial": "Tecartus", "eu_brand_name_current": "Not parsed", "active_substance": "brexucabtagene autoleucel", "eu_nas": false, "eu_atmp": false, "eu_od_initial": "Not parsed", "eu_mah_initial": "Not parsed", "eu_aut_type_initial": "Not parsed", "eu_aut_type_current": "conditional", "eu_mah_current": "Kite Pharma EU B.V."}], "annexes": [{"pdf_file": "EU-1-20-1492_h_anx_0.pdf", "xml_file": "EU-1-20-1492_h_anx_0.xml", "is_initial": true, "creation_date": "D:20201110131647-05'00'", "modification_date": "D:20201110131810-05'00'", "eu_aut_type_initial": "conditional", "eu_med_type": "small molecule"}, {"pdf_file": "EU-1-20-1492_h_anx_1.pdf", "xml_file": "EU-1-20-1492_h_anx_1.xml", "is_initial": false, "creation_date": "D:20220110113647Z", "modification_date": "D:20220110114531Z"}, {"pdf_file": "EU-1-20-1492_h_anx_2.pdf", "xml_file": "EU-1-20-1492_h_anx_2.xml", "is_initial": false, "creation_date": "D:20220825143159+02'00'", "modification_date": "D:20220825152135+01'00'"}], "epars": [{"filename": "EU-1-20-1492_h_public-assessment-report", "ema_procedure_start_initial": "12/12/2019", "chmp_opinion_date": "15/10/2020", "eu_legal_basis": ["article 8.3"], "eu_prime_initial": "yes", "ema_rapp": "jan mueller-berghaus", "ema_corapp": "rune kjeken", "ema_reexamination": "no", "eu_accel_assess_g": "yes"}], "omars": [{"pdf_file": "EU-1-20-1492_h_omar.pdf", "xml_file": "EU-1-20-1492_h_omar.xml", "creation_date": "D:20201215120758+01'00'", "modification_date": "D:20201215121020+01'00'", "ema_omar_condition": [{"eu_od_number": "eu/3/19/2220", "ema_prevalence": "the prevalence of mantle cell lymphoma (hereinafter referred to as \u201cthe condition\u201d) was estimated to remain below 5 in 10,000 and was concluded to be 0.6 in 10,000 persons in the european union, at the time of the review of the designation criteria; ", "ema_alternative_treatments": "significant_benefit", "ema_significant_benefit": "|->NOT FOUND<-|"}]}]}